EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre‐ or post‐stem cells

Hugues deLavallade, William Wilson, Rachel Protheroe, Matthew Smith, Darren Edwards, Katie O'Donnell, Eleni Tholouli, Shankaranarayan Paneesha, Matthew Collin, Ben Uttenthal, David Irvine, MonMon Yee iD und 6 weitere

British Journal of Haematology · 2026-05 · 208 (5) · 1758-1767

DOI: 10.1111/bjh.70429 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 25.03.2026. Verfasst von Hugues deLavallade und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Guys and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Transplantation Conditioning, Peripheral Blood Stem Cell Transplantation, Cyclophosphamide, Hematologic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Blood Cancer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This prospective phase 2 multicentre non‐randomised parallel arm study of haploidentical peripheral blood stem cell (PBSC) transplantation with post‐transplant cyclophosphamide (PTCy) recruited 77 patients: 50 received reduced‐intensity conditioning (RIC) with PTCy post stem cell infusion while 27 underwent myeloablative conditioning (MAC) with PTCy given after lymphocyte but prior to infusion of CD34 selected stem cells. The primary end‐point 1‐year overall survival (OS) was 86% for RIC and 78% for MAC, meeting the pre‐specified targets for efficacy. At 4 years, OS was 63% for RIC and 60% for MAC with low non‐relapse mortality of RIC 18% and MAC 4%. Engraftment was faster in the MAC arm (median time to neutrophil and platelet engraftment 11 and 15 days; 21 and 24 days in the RIC arm). The economic analysis showed that MAC had higher initial transplant costs, RIC incurred greater post‐transplant monitoring costs, resulting in higher overall costs (RIC £156 711, MAC £131 092). Quality of life (QoL) outcomes in both indicated significant post‐transplant declines at 3 months but returned to baseline by 12 months. This study confirms the long‐term safety of using PBSC with PTCy in haploidentical transplants, with a good quality of life and reasonable costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transplantation ConditioningPeripheral Blood Stem Cell TransplantationCyclophosphamideHematologic NeoplasmsHumansAdultFemaleProspective StudiesMaleMiddle AgedTransplantation, HaploidenticalUnited KingdomAdolescentYoung AdultGraft vs Host DiseaseQuality of Life

Stichwörter der Autor:innen

PTCyhaploidentical transplant

Substanzen

Cyclophosphamide

Autor:innen und Institutionen

  • Department of Haematology, Guys and St Thomas' NHS Foundation Trust, London, UK.
  • UCL Cancer Trials Centre, Kings College Hospital NHS Foundation Trust, London, UK.
  • Department of Haematology, King's College London, London, UK.
  • Department of Haematology, University College London Cancer Research UK & UCL Cancer Trials Centre, London, UK.
  • Department of Haematology, University Hospital Bristol NHS Foundation Trust, Bristol, UK.
  • Department of Haematology, Barts Health NHS Trust, London, UK.

ORCID-Profile: MonMon Yee, Kavita Raj

Förderung

  • Blood Cancer UK

Zitieren

APA

deLavallade, H., Wilson, W., Protheroe, R., Smith, M., Edwards, D., O'Donnell, K., Tholouli, E., Paneesha, S., Collin, M., Uttenthal, B., Irvine, D., Yee, M., Tappenden, P., Kottaridis, P., Snowden, J. A., Mackinnon, S., Pagliuca, A., & Raj, K. (2026). Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre‐ or post‐stem cells. British Journal of Haematology, 208(5), 1758-1767. https://doi.org/10.1111/bjh.70429

Vancouver

deLavallade H, Wilson W, Protheroe R, Smith M, Edwards D, O'Donnell K, et al. Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre‐ or post‐stem cells. British Journal of Haematology. 2026;208(5):1758-1767. doi:10.1111/bjh.70429

BibTeX
@article{deLavallade2026,
  author = {deLavallade, Hugues and Wilson, William and Protheroe, Rachel and Smith, Matthew and Edwards, Darren and O'Donnell, Katie and Tholouli, Eleni and Paneesha, Shankaranarayan and Collin, Matthew and Uttenthal, Ben and Irvine, David and Yee, MonMon and Tappenden, Paul and Kottaridis, Panagiotis and Snowden, John A and Mackinnon, Steven and Pagliuca, Antonio and Raj, Kavita},
  title = {Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre‐ or post‐stem cells},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {5},
  pages = {1758--1767},
  doi = {10.1111/bjh.70429}
}
Kostenlos starten →